Artiva Biotherapeutics, Inc. Common Stock (ARTV) Stock Forecast & Price Target
Artiva Biotherapeutics, Inc. Common Stock · NASDAQ
$10.48+0.16 (+1.55%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Artiva Biotherapeutics, Inc. Common Stock, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $35.00 to $41.00, so the covering firms are broadly aligned. The average target of $39.00 sits 272% above the current $10.48. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.52 next quarter toward $-2.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Artiva Biotherapeutics, Inc. Common Stock.
As of Jul, 4 of 4 firms rate ARTV a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARTV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-0.56 – $-0.50 · 4 analysts · -41% YoY
Next period, 4 analysts expect Artiva Biotherapeutics, Inc. Common Stock to earn $-0.52 a share (range $-0.56 – $-0.50), versus $-0.88 a year earlier. Full-year consensus is $-2.43, growing to $-2.81 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Artiva Biotherapeutics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARTV.
#1
David Nierengarten
Wedbush · Rank #115
Buy
$18.00+71.8% to target
Overall win rate
41%
+ Follow
#2
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
$40.00+281.7% to target
Overall win rate
38%
+ Follow
#3
EW
Edward White
HC Wainwright & Co. · Rank #241
Buy
$20.00+90.8% to target
Overall win rate
31%
+ Follow
#4
Gil Blum
Needham · Rank #298
Buy
$41.00+291.2% to target
Overall win rate
24%
+ Follow
#5
Emily Bodnar
HC Wainwright & Co. · Rank #338
Buy
$35.00+234.0% to target
Overall win rate
22%
+ Follow
ARTV stock forecast FAQ
What is ARTV's average 12-month price target?+
The 4 analysts with a live target average $39.00 for Artiva Biotherapeutics, Inc. Common Stock over the next 12 months, ranging from a $41.00 high to a $35.00 low.
Is ARTV stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ARTV?+
The Street-high target is $41.00 (Needham), and the Street-low is $35.00 (HC Wainwright & Co.). The average of all 4 active targets is $39.00.
How many Wall Street analysts cover ARTV?+
4 analysts have an active rating on Artiva Biotherapeutics, Inc. Common Stock, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering ARTV?+
Among analysts who currently cover ARTV, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #115). Their current call is Buy with a $18.00 target.
What is Artiva Biotherapeutics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-0.56 – $-0.50) across 4 analysts. Full-year EPS is projected at $-2.43, rising to $-2.81 the following year.
How much revenue is Artiva Biotherapeutics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ARTV lately?+
As of Jul, 4 of 4 firms rate ARTV a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARTV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
